The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]

  • See Evidence submitted by expert panel for details.

Variant: NM_000152.5(GAA):c.1143del (p.Ala382fs)

CA8815181

370263 (ClinVar)

Gene: GAA
Condition: glycogen storage disease II
Inheritance Mode: Autosomal recessive inheritance
UUID: 6121e8fb-aef5-418f-98d7-337d796d4f45

HGVS expressions

NM_000152.5:c.1143del
NM_000152.5(GAA):c.1143del (p.Ala382fs)
NM_000152.3:c.1143del
NM_001079803.1:c.1143del
NM_001079804.1:c.1143del
NM_000152.4:c.1143del
NM_001079803.2:c.1143del
NM_001079804.2:c.1143del
NM_001079803.3:c.1143del
NM_001079804.3:c.1143del
ENST00000302262.7:c.1143del
ENST00000390015.7:c.1143del
NC_000017.11:g.80108556del
CM000679.2:g.80108556del
NC_000017.10:g.78082355del
CM000679.1:g.78082355del
NC_000017.9:g.75696950del
NG_009822.1:g.12001del

Pathogenic

Met criteria codes 4
PP4 PM3_Supporting PM2 PVS1

Evidence Links 5

Expert Panel

Criteria Specification Information

Criteria Specifications for this VCEP
Evidence submitted by expert panel
Lysosomal Diseases VCEP
This variant, c.1143del (p.Ala382LeufsTer10), is a frameshift variant that is predicted to result in a premature termination codon, nonsense mediated decay, and lack of gene product, meeting PVS1. The highest population minor allele frequency in gnomAD v2.1.1 0.000008946 in the European non-Finnish population, meeting PM2. At least five individuals with late onset Pompe disease (believed to be different individuals based on age of onset and age at report) who are compound heterozygous for the variant and c.-32-13T>G have been reported (PMIDs 22676651, 24383498, 25155446, 29122469, 29315315, 30564623), and three of them meet the ClinGen LSD VCEP’s specifications for PP4 (PMID 22676651, 29122469). The phase of the variants is unknown for all of these patients. PM3_Supporting is met based on the specifications on the Clingen LSD VCEP. There is a ClinVar entry for this variant (Variation ID: 370263, 1 star review status) with one submitter classifying the variant as pathogenic and one as likely pathogenic. In summary, this variant meets the criteria to be classified as pathogenic for Pompe disease. GAA-specific ACMG/AMP criteria applied, as specified by the ClinGen LSD VCEP: PVS1, PM2, PM3_Supporting, PP4.
Met criteria codes
PP4
Three individuals have residual GAA activity in the affected range in leukocytes, or reduced GAA activity in fibroblasts (6.25%) and muscle, meeting the ClinGen LSD VCEP's specifications for PP4 (PMID 22676651, 29122469).

PM3_Supporting
At least five individuals with late onset Pompe disease (believed to be different individuals based on age of onset and age at report) who are compound heterozygous for the variant and c.-32-13T>G have been reported (PMIDs 22676651, 24383498, 25155446, 29122469, 29315315, 30564623), and three of them meet the ClinGen LSD VCEP’s specifications for PP4 (PMID 22676651, 29122469). The phase of the variants is unknown for all of these patients. PM3_Supporting (0.5 points) is met based on counting no more than one individual with the same genotype if not confirmed in trans.

PM2
The highest population minor allele frequency in gnomAD v2.1.1 is 0.000008946 in the European non-Finnish population, which is lower than the ClinGen LSD VCEP threshold (<0.001) for PM2, meeting this criterion.
PVS1
This is a frameshift variant which is predicted to result in a premature termination codon, nonsense mediated decay, and lack of gene product. Therefore, PVS1 can be applied.
Approved on: 2020-08-31
Published on: 2020-11-12
The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.
¤ Powered by BCM's Genboree.